Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 3q27 3 Microdeletion Syndrome C4749427
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 3q27 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
3q27 3 Microdeletion Syndrome C4749427
A rare chromosomal condition where a small piece of chromosome 3 is missing. It can affect physical development, growth, and learning. Management involves specialized care to address specific symptoms.
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
3q27 3 Microdeletion Syndrome C4749427
0-0
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
3q27 3 Microdeletion Syndrome C4749427
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
3q27 3 Microdeletion Syndrome C4749427
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
3q27 3 Microdeletion Syndrome C4749427
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3q27 3 Microdeletion Syndrome C4749427
congenital
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3q27 3 Microdeletion Syndrome C4749427
genetic
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 3q27-3-microdeletion-syndrome-C4749427 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3q27 3 Microdeletion Syndrome C4749427 | Discriminating power |
|---|---|---|---|
| Neurologic features | Developmental delay, seizures, and movement difficulty are described. | Learning and developmental effects may occur; seizures are not established as typical. | Moderate |
| Growth and body development | Primarily neurologic and metabolic; characteristic physical anomalies are not established. | May affect physical development and growth. | Moderate |
| Serine metabolism | Impaired serine production may cause low serine on specialized testing. | No serine-synthesis defect is established from the deletion alone. | High |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Early seizures with developmental delay
Fits the described neurologic metabolic pattern, but confirmation is required.
Moderate
Low serine on amino-acid testing
Supports a serine-biosynthesis disorder; the result alone is not a diagnosis.
High
Biallelic PHGDH variants
Genetic confirmation distinguishes enzyme deficiency from a chromosomal deletion.
High
Choose 3q27 3 Microdeletion Syndrome C4749427 when
Congenital growth or learning concerns
Better matches the described chromosomal phenotype than a primary serine defect.
Moderate
Microarray shows 3q27.3 deletion
Supports the microdeletion when reviewed by a genetics clinician.
High
Normal serine studies
Makes PHGDH deficiency less likely but does not prove the deletion.
Moderate
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3q27 3 Microdeletion Syndrome C4749427 | Interpretation |
|---|---|---|---|
| Plasma or CSF amino acids | Serine may be low; exact cutoffs are not supplied. | No specific amino-acid abnormality is established. | An abnormal result suggests, but does not alone diagnose, PHGDH deficiency. |
| PHGDH genetic testing | Biallelic pathogenic variants support the diagnosis. | Not the primary test and may be normal. | Interpret with biochemistry and clinical genetics review. |
| Chromosomal microarray | Usually nondiagnostic for this enzyme deficiency. | May detect a 3q27.3 microdeletion. | A deletion needs clinical correlation and does not assess serine metabolism. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- Often described as a severe chronic neurologic disorder; individual outcome is not established.
- Factors
- Seizure burden, developmental impact, recognition timing, and response to clinician-directed care.
3q27 3 Microdeletion Syndrome C4749427
- Outcome
- Described as moderate but variable; exact prognosis is not established.
- Factors
- Deletion findings, growth, learning needs, and associated congenital features.
Time frame: Both are lifelong early-onset or congenital conditions.
No prevalence or mortality figures are supplied; prognosis requires individualized clinical assessment.
Complications comparison
| Complication | Presentation |
|---|---|
| Seizures | A described neurologic feature requiring individualized care. Not established as characteristic. Seizure risk should not be assumed to be equivalent. |
| Developmental or learning difficulty | Developmental delay is described and may be severe. Learning difficulty is described within a generally moderate phenotype. Individual severity cannot be predicted from these labels alone. |
| Movement or growth problems | Movement difficulty is described; growth effects are not established. Growth and physical development may be affected. Needs should be defined through multidisciplinary assessment. |
Patient education highlights
- HighDifferent causes
One is a metabolic enzyme disorder; the other is a chromosomal microdeletion.
- HighTest interpretation
Amino-acid and genetic results need specialist review and are not diagnoses by themselves.
- MediumCare planning
Support is individualized. Medication choices and doses must come from the treating clinician.